Lamotrigine

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy, Lennox-Gastaut Syndrome, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
JP
  • Use as adjunctive treatment with other antiepileptic drugs for partial seizures (including secondary generalized seizures), tonic-clonic seizures, and generalized seizures associated with Lennox-Gastaut syndrome in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective
Product first approved 2008PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (38)
Bipolar Disorder
NCT06929273 · Bristol-Myers Squibb
2025-07-18 – 2028-06-13 · Bipolar Disorder Type I With Mania
What this study did
NCT00723450 · GlaxoSmithKline
2008-07 – 2013-08 · Bipolar Disorder
What this study did
NCT00566020 · GlaxoSmithKline
2008-05 – 2010-10 · Bipolar Disorder
What this study did
NCT00621842 · University Hospitals Cleveland Medical Center
2008-01 – 2010-03 · Bipolar Disorder, Depression, Bipolar
What this study did
NCT00550407 · GlaxoSmithKline
2007-11 – 2009-10 · Bipolar Disorder
What this study did
NCT00221975 · University Hospitals Cleveland Medical Center
2002-07 – 2007-12 · Bipolar Disorder
What this study did
NCT00074776 · Stanford University
2003-05 – 2007-10 · Bipolar Disorder
What this study did
NCT00063362 · University Hospitals Cleveland Medical Center
2002-02 – 2007-07 · Bipolar Disorder
What this study did
NCT00226135 · University of Aarhus
2001-03 – 2006-12 · Bipolar Disorder
What this study did
NCT00224510 · GlaxoSmithKline
2002-08 – 2006-09 · Bipolar Disorder, Bipolar Depression
What this study did
NCT00056277 · GlaxoSmithKline
2003-02-27 – 2005-12-14 · Bipolar Disorder
What this study did
Epilepsy
NCT01891890 · Emory University
2013-08 – 2015-10-23 · Epilepsy, Partial, Epilepsy, Localization Related
What this study did
NCT01431963 · GlaxoSmithKline
2011-09 – 2014-10 · Epilepsy
What this study did
NCT00516139 · GlaxoSmithKline
2007-08 – 2010-07 · Epilepsy
What this study did
NCT00395694 · GlaxoSmithKline
2006-08-07 – 2009-03-26 · Epilepsy
What this study did
NCT00242606 · Philipps University Marburg
2005-03 – 2009-01 · Epilepsy
What this study did
NCT00355082 · GlaxoSmithKline
2006-05 – 2008-11 · Epilepsy, Partial
What this study did
NCT00113165 · GlaxoSmithKline
2004-10 – 2007-07 · Epilepsy, Epilepsy, Partial
What this study did
NCT00264615 · GlaxoSmithKline
2005-10 – 2006-06 · Epilepsy
What this study did
NCT00266149 · University of Aarhus
2003-06 – 2005-05 · Epilepsy
What this study did
Other / comorbidity
NCT05017155 · University College, London
2021-08-12 – 2024-04-02 · Non-Dystrophic Myotonia
What this study did
NCT03831854 · The Cleveland Clinic
2019-01-24 – 2020-12-31 · Reducing Psychological Side Effects of Ketamine
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT00571246 · Yale University
2012-06 – 2016-06 · Alcohol Dependence, Post Traumatic Stress Disorder
What this study did
NCT01939561 · Grete Andersen, MD
2013-11 – 2015-11 · Dystrophia Myotonica Type 1, Myotonia Congenita, Paramyotonia Congenita, Hyperkalemic Periodic Paralysis, Potassium-Aggravated Myotonia
What this study did
NCT01042496 · Mayo Clinic
2009-12 – 2014-10 · Bipolar Depression
What this study did
NCT00068445 · Alliance for Clinical Trials in Oncology
2004-02 – 2013-11 · Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
What this study did
NCT00277641 · Lindner Center of HOPE
2006-03 – 2009-01 · Binge Eating Disorder, Obesity
What this study did
NCT00579982 · GlaxoSmithKline
2008-01 – 2008-02 · Mood Disorders
What this study did
NCT00652171 · Institute of Social Security of the Civil Servants of Minas Gerais
2004-01 – 2006-01 · Depression
What this study did
NCT00086593 · GlaxoSmithKline
2004-05 – 2005-07 · Schizophrenia
What this study did
NCT00071747 · GlaxoSmithKline
2003-08 – 2005-01 · Schizophrenia
What this study did
Phase 2/3 (4)
Other / comorbidity
NCT02256124 · Erasmus Medical Center
2014-10 – 2020-04 · Neurofibromatosis Type 1
What this study did
NCT02556060 · Taipei City Hospital
2015-09 – 2017-05-01 · Addiction
What this study did
NCT00913107 · University of Malaya
2007-09 – 2008-06 · Trigeminal Neuralgia
What this study did
NCT00295776 · George Washington University
2005-02 – 2007-12 · Neuralgia, Postherpetic
What this study did
Phase 2 (17)
Bipolar Disorder
NCT00475137 · University of British Columbia
2007-12 – 2015-06 · Bipolar II Disorder, Most Recent Episode Major Depressive
What this study did
NCT00176228 · University of Illinois at Chicago
2004-02 – 2008-01 · Bipolar Disorder
What this study did
NCT00206778 · Beth Israel Medical Center
2003-07 – 2007-07 · Mixed Mania Bipolar Disorder
What this study did
Epilepsy
NCT03220256 · Seoul National University Hospital
2016-08-02 – 2018-08-01 · Lamotrigine Allergy
What this study did
NCT00044278 · GlaxoSmithKline
2000-09 – 2006-06 · Epilepsy
What this study did
NCT00043875 · GlaxoSmithKline
2000-05 – 2003-11 · Epilepsy
What this study did
Other / comorbidity
NCT05420350 · Dent Neuroscience Research Center
2020-12-16 – 2024-12 · Meniere Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
What this study did
NCT04770493 · Brown University
2022-01-24 – 2024-10-24 · Alcohol Use Disorder
What this study did
NCT03504501 · Technical University of Munich
2019-03-22 – 2023-10-31 · Impaired Synaptic Plasticity, Impaired Cognition
What this study did
NCT02158585 · Dent Neuroscience Research Center
2014-06 – 2017-03 · Meniere's Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
What this study did
NCT00917839 · Cantonal Hospital of St. Gallen
2009-06 – 2011-12 · Relapsing-Remitting Multiple Sclerosis
What this study did
NCT00513019 · University of Chicago
2007-08 – 2009-09 · Neurotic Excoriation, Pathologic Skin Picking, Psychogenic Excoriation, Dermatillomania
What this study did
NCT00257855 · University College London Hospitals
2005-11 – 2009-02 · Secondary Progressive Multiple Sclerosis
What this study did
NCT00269594 · University of Minnesota
2006-01 – 2006-09 · Neurotic Disorders, Obsessive-Compulsive Disorder
What this study did
NCT00001482 · National Institute of Mental Health (NIMH)
1995-05 – 2001-05 · Anxiety Disorder, Mood Disorder, Psychotic Disorder
What this study did
NCT00015106 · National Institute on Drug Abuse (NIDA)
1997-11 – 1999-02 · Cocaine-Related Disorders
What this study did
NCT00000192 · Yale University
1993-01 – 1998-01 · Opioid-Related Disorders
What this study did
Phase 1/2 (1)
Bipolar Disorder
NCT00789113 · University of Minnesota
2008-11 – 2011-01 · Epilepsy, Seizures, Bipolar Disorder, Bipolar Depression
What this study did
Phase 1 (44)
Bipolar Disorder
NCT02513654 · GlaxoSmithKline
2015-09-06 – 2015-11-11 · Bipolar Disorder
What this study did
NCT00488566 · Biogen
2007-05-31 – 2008-05-31 · Bipolar Disorder
What this study did
Epilepsy
NCT03695094 · UCB Biopharma S.P.R.L.
2018-09-18 – 2019-05-30 · Epilepsy
What this study did
NCT02707965 · Food and Drug Administration (FDA)
2017-06-08 – 2018-09-04 · Epilepsy
What this study did
NCT02064465 · GlaxoSmithKline
2014-03-15 – 2014-07-08 · Epilepsy
What this study did
NCT01357902 · GlaxoSmithKline
2011-04-18 – 2011-05-23 · Epilepsy
What this study did
NCT00627575 · GlaxoSmithKline
2008-02-04 – 2008-09-12 · Epilepsy
What this study did
NCT00605371 · GlaxoSmithKline
2008-01-15 – 2008-03-06 · Epilepsy
What this study did
NCT00412191 · GlaxoSmithKline
2007-02-06 – 2007-04-27 · Epilepsy
What this study did
NCT02283801 · Bial - Portela C S.A.
2006-11 – 2007-01 · Epilepsy
What this study did
NCT00144872 · GlaxoSmithKline
2004-11-01 – 2006-04-22 · Seizure, Absence
What this study did
Other / comorbidity
NCT06729970 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
2024-12-26 – 2026-01-23 · Healthy Volunteers
What this study did
NCT06199791 · Desitin Arzneimittel GmbH
2023-04-03 – 2023-06-14 · Fasting
What this study did
NCT04602221 · Boehringer Ingelheim
2020-12-01 – 2022-08-12 · Healthy
What this study did
NCT04938856 · University of Karachi
2020-09-04 – 2020-10-25 · Bioequivalence
What this study did
NCT02708849 · Yale University
2015-06 – 2020-03 · Mental Disorders
What this study did
NCT04015687 · Agios Pharmaceuticals, Inc.
2019-07-15 – 2019-10-09 · Healthy Participants
What this study did
NCT03898011 · Pharmtechnology LLC
2019-03-23 – 2019-05-04 · Healthy Adults
What this study did
NCT05145608 · Alembic Pharmaceuticals Ltd.
2018-01-10 – 2018-02-21 · Bioequivalence
What this study did
NCT02821338 · Food and Drug Administration (FDA)
2016-06 – 2017-04 · Healthy
What this study did
NCT01618799 · IPCA Laboratories Ltd.
2012-03 – 2012-05 · Fasting State
What this study did
NCT01618825 · IPCA Laboratories Ltd.
2012-03 – 2012-05 · Fed
What this study did
NCT01888757 · Dr. Reddy's Laboratories Limited
2010-09 – 2010-10 · Healthy
What this study did
NCT01888263 · Dr. Reddy's Laboratories Limited
2010-08 – 2010-09 · Healthy
What this study did
NCT01888731 · Dr. Reddy's Laboratories Limited
2010-08 – 2010-09 · Healthy
What this study did
NCT01888250 · Dr. Reddy's Laboratories Limited
2010-08 – 2010-09 · Healthy
What this study did
NCT00618241 · Radboud University Medical Center
2008-02 – 2008-10 · HIV Infection
What this study did
NCT01607086 · GlaxoSmithKline
2008-07-11 – 2008-07-18 · Mental Disorders
What this study did
NCT00449774 · GlaxoSmithKline
2007-05-07 – 2007-06-19 · Mental Disorders
What this study did
NCT00410371 · GlaxoSmithKline
2006-12-28 – 2007-01-25 · Mental Disorders
What this study did
NCT00647751 · Mylan Pharmaceuticals Inc
2004-08 – 2004-08 · Healthy
What this study did
NCT00650208 · Mylan Pharmaceuticals Inc
2004-07 – 2004-08 · Healthy
What this study did
NCT01131975 · Dr. Reddy's Laboratories Limited
2003-01 – 2003-03 · Healthy
What this study did
NCT01131949 · Dr. Reddy's Laboratories Limited
2003-01 – 2003-03 · Healthy
What this study did
NCT01513720 · Dr. Reddy's Laboratories Limited
2002-12 – 2002-12 · Healthy
What this study did
NCT01513681 · Dr. Reddy's Laboratories Limited
2002-11 – 2002-11 · Healthy
What this study did
NCT00838136 · Teva Pharmaceuticals USA
2002-02 – 2002-03 · Healthy
What this study did
NCT00838279 · Teva Pharmaceuticals USA
2002-02 – 2002-03 · Healthy
What this study did
NCT00835263 · Teva Pharmaceuticals USA
2002-01 – 2002-02 · Healthy
What this study did
NCT00834561 · Teva Pharmaceuticals USA
2002-01 – 2002-02 · Healthy
What this study did
Phase 4 (36)
Bipolar Disorder
NCT02389712 · Mayo Clinic
2015-03 – 2018-05-23 · Bipolar Disorder
What this study did
NCT02989727 · University of Saskatchewan
2003-11 – 2017-12 · Depression, Bipolar Disorder, Bipolar Depression, Melancholia, Lamotrigine
What this study did
NCT01588457 · The University of Texas Health Science Center at San Antonio
2011-06 – 2016-12 · Bipolar I Disorder, Bipolar II Disorder
What this study did
NCT01015586 · Medical University of South Carolina
2010-02 – 2014-09 · Alcohol Dependence, Bipolar Disorder, Depression, Mania, Psychosis
What this study did
NCT01864551 · Tri-Service General Hospital (TSGH)
2008-08 – 2012-09 · Bipolar Disorder
What this study did
NCT00280293 · University of Texas Southwestern Medical Center
2006-03 – 2010-01 · Bipolar Disorder, Cocaine Dependence
What this study did
NCT00277212 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-12-01 – 2009-07-01 · Bipolar Disorder
What this study did
NCT00183469 · The University of Texas Health Science Center at San Antonio
2004-12 – 2009-04 · Bipolar Disorder, Depression
What this study did
NCT00181844 · Massachusetts General Hospital
2005-01 – 2008-04 · Bipolar Disorder, Mania
What this study did
NCT00223509 · The University of Texas Health Science Center at San Antonio
2005-08 – 2007-11 · Bipolar Disorder
What this study did
NCT00360126 · GlaxoSmithKline
2005-10 – 2007-02 · Bipolar Disorder
What this study did
NCT00188643 · University Health Network, Toronto
2002-01 – 2007-01 · Bipolar Disorder
What this study did
NCT00485771 · Eli Lilly and Company
2003-11 – 2005-01 · Bipolar Disorder
What this study did
NCT00067938 · GlaxoSmithKline
2003-08 – 2004-08 · Bipolar Disorder
What this study did
NCT00177567 · University of Pittsburgh
2001-07 – 2004-01 · Bipolar Disorder
What this study did
Epilepsy
NCT05881928 · Assiut University
2024-07-29 – 2025-04 · Epilepsy, Lamotrigine, Sodium Valproate Adverse Reaction
What this study did
NCT03689114 · Mario Negri Institute for Pharmacological Research
2021-05-10 – 2024-06-30 · Epilepsies, Partial
What this study did
NCT05748236 · Dhaka Medical College
2022-11-01 – 2023-10 · Focal Epilepsy
What this study did
NCT01733394 · University of Cincinnati
2012-12-12 – 2016-09-26 · Epilepsy
What this study did
NCT02404168 · University of Maryland, Baltimore
2015-07-07 – 2016-04-06 · Epilepsy
What this study did
NCT01713777 · University of Cincinnati
2013-04 – 2015-09 · Epilepsy
What this study did
NCT01995825 · University of Maryland, Baltimore
2012-05 – 2013-10 · Epilepsy
What this study did
NCT00807989 · Yonsei University
2008-03 – 2012-05 · Epilepsy
What this study did
NCT00438451 · Johannes Gutenberg University Mainz
2007-01 – 2011-08 · Focal Epilepsy
What this study did
NCT00896987 · Korean Epilepsy Society
2006-05 – 2008-12 · Epilepsy
What this study did
NCT00137709 · Chinese University of Hong Kong
2004-11 – 2008-07 · Epilepsy
What this study did
NCT00043901 · GlaxoSmithKline
2000-12-01 – 2005-03-01 · Epilepsy, Tonic-Clonic
What this study did
NCT00043914 · GlaxoSmithKline
2002-01-14 – 2003-01-29 · Epilepsy
What this study did
Other / comorbidity
NCT01142310 · University of Texas Southwestern Medical Center
2010-06 – 2015-06 · Memory Impairment
What this study did
NCT02303106 · Per Damkier
2014-11 – 2015-04 · Healthy
What this study did
NCT00419003 · Baylor College of Medicine
2006-12 – 2008-09 · Major Depression
What this study did
NCT00634062 · Mclean Hospital
2004-12 – 2007-09 · Borderline Personality Disorder
What this study did
NCT00947375 · Central Mental Clinic for Outpatients of Baku City
2005-01 – 2007-01 · Schizophrenia
What this study did
NCT00223262 · University of Texas Southwestern Medical Center
2002-08 – 2005-09 · Memory Impairment Due to Corticosteroid Use, Hypomania Due to Corticosteroid Use, Hippocampal Atrophy Due to Corticosteroid
What this study did
NCT00153244 · Centre of Chinese Medicine, Georgia
2002-08 – 2003-05 · Bronchial Asthma
What this study did
Early phase / not applicable (14)
Bipolar Disorder
NCT01880957 · Stony Brook University
2011-11-08 – 2017-06-23 · Bipolar Disorder, Bipolar Depression, Unipolar Depression
What this study did
NCT01463111 · Emory University
2011-05 – 2016-04 · Bipolar Disorder
What this study did
NCT00012558 · National Institute of Mental Health (NIMH)
1998-09 – 2005-09 · Bipolar Disorder
What this study did
Epilepsy
NCT04939675 · National Taiwan University Hospital
2021-07-01 – 2025-06-30 · Epilepsy
What this study did
NCT00916149 · Massachusetts General Hospital
2007-01 – 2012-10 · Epilepsy
What this study did
NCT00208520 · Dutch Epilepsy Clinics Foundation
2003-07 – 2007-06 · Adults With Tonic Clonic Seizures and/or Partial Seizures
What this study did
Other / comorbidity
NCT05639257 · Grete Andersen, MD
2022-12-05 – 2024-04-01 · Non-Dystrophic Myotonia
What this study did
NCT04156035 · Charite University, Berlin, Germany
2020-03-10 – 2020-12-10 · Emotions
What this study did
NCT04396938 · University of Oxford
2017-05-10 – 2019-08-30 · Healthy
What this study did
NCT00720473 · Mclean Hospital
2006-04 – 2011-12 · Bipolar Depression
What this study did
NCT00243152 · Pain and Analgesia Imaging and Neuroscience Group
2005-10 – 2008-07 · Facial Neuropathy
What this study did
NCT00901407 · Louisiana State University Health Sciences Center in New Orleans
2003-12 – 2007-04 · Unipolar Depression
What this study did
NCT00284791 · MaineHealth
2006-01 – 2007-02 · Adolescent Depression
What this study did
NCT00203229 · Thomas Jefferson University
2003-06 – 2006-07 · Trigeminal Neuralgia
What this study did
Used as active comparator (6)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Bipolar Disorder
NCT00274677 · GlaxoSmithKline
2003-11 – 2005-08 · Bipolar Disorder
What this study did
Epilepsy
NCT00280059 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006-08 – 2010-04 · Epilepsy, Partial
What this study did
Phase 1 (1)
Bipolar Disorder
NCT02081287 · San Diego Veterans Healthcare System
2014-05 – 2018-07-30 · Bipolar Disorder, Manic Depression
What this study did
Phase 4 (3)
Bipolar Disorder
NCT06184581 · University Hospital Bispebjerg and Frederiksberg
2024-05-08 – 2027-12-01 · Bipolar II Disorder
What this study did
Epilepsy
NCT05697614 · Dr Cipto Mangunkusumo General Hospital
2023-03-01 – 2023-06-30 · Drug Resistant Epilepsy
What this study did
Other / comorbidity
NCT00926835 · Ministry of Health & Welfare, Korea
2009-05 – 2015-07 · Major Depressive Disorder
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Bipolar Disorder
NCT01674010 · OPKO Health, Inc.
2012-08 – 2014-06 · Bipolar 1 Disorder
What this study did
Phase 4 (3)
Epilepsy
NCT00855738 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2007-05 – 2009-06 · Focal Epilepsy
What this study did
Other / comorbidity
NCT04523935 · Sathbhavana Brain Clinic
2005-12-07 – 2020-08-04 · Cerebral Palsy, Excessive Crying, Pain
What this study did
NCT03161509 · Rambam Health Care Campus
2017-07-01 – 2019-01-01 · Bariatric Surgery Candidate
What this study did
Early phase / not applicable (1)
Bipolar Disorder
NCT00531518 · MaineHealth
2007-10 – 2013-09 · Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Lamotrigine: this drugApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Lamotrigine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Phase 3Bipolar DisorderRecruiting
Est. primary completion 2028-06-13 · NCT06929273 · CT.gov ↗
What to watch

See the full readout calendar ↗